Axcella flunks long Covid PhII primary goal — but plots a path into PhIII
As Covid-19 cases mount once again and millions of people experience lingering symptoms months after diagnosis, Axcella Therapeutics wants to treat long Covid, but like others in the past, it has failed to meet the primary goal of a mid-stage study.
The biotech isn’t giving up on the pandemic disease’s long-term effects, unlike the move that PureTech Health made after missing the beat in its own Phase II last month. Axcella will attempt to persuade regulators in the US and UK with fatigue scores from the Phase IIa, rather than the missed primary goal, in discussions about a potential registrational Phase III study following.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.